Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

100.0%

3 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01263366Phase 1Terminated

Exploratory Study of Norepinephrine to Prevent Radiodermatitis in Breast Cancer Patients

Role: lead

NCT01544504Phase 1Withdrawn

Exploratory Study of Topical Norepinephrine in Breast Cancer Patients Receiving Radiotherapy

Role: lead

NCT01367990Phase 1Terminated

Exploratory Study of Norepinephrine to Prevent Alopecia in Head and Neck Cancer Patients Treated With Radiotherapy

Role: lead

All 3 trials loaded